Mandate

Skandia Investment and Investor Growth Capital acquire Swedish Orphan International

May 12, 2005

A consortium comprising of Investor Growth Capital (IGC), Skandia Investment (SI), the Swedish private equity firms and the CEO of Swedish Orphan International AB (SOI) have agreed to acquire the company. SOI is a Sweden based company with the business concept to develop, register, market and distribute orphan drugs, which are pharmaceuticals used in the treatment of rare disorders, for an undisclosed sum.

Vinge acted for Investor Growth Capital and Skandia Investment.
Ulf Sallnäs (responsible partner)
Helena Dandenell, Kristoffer Persson (associates)

Related

Vinge advises Pricer in connection with Vusion’s public takeover offer

On 17 November 2026, VusionGroup S.A., a French public limited company listed on Euronext Paris, announced a recommended public takeover offer to the shareholders of Pricer Aktiebolag (publ) to acquire all shares in Pricer for a consideration of SEK 6.00 per share. The offer values all shares in Pricer at approximately SEK 980.4 million.
November 20, 2026

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026